UBC Cancer Research Reveals Biological Diversity in Hodgkin Lymphoma Subtypes

Understanding the Breakthrough: A New Lens on Classic Hodgkin Lymphoma

Classic Hodgkin lymphoma (cHL), a type of blood cancer characterized by rare malignant cells known as Hodgkin and Reed-Sternberg (HRS) cells embedded in a complex web of immune cells, has long been treated as a relatively uniform disease. However, researchers at the BC Cancer Research Centre and the University of British Columbia (UBC) have upended this perspective with a groundbreaking study published on January 30, 2026, in the prestigious journal Cancer Discovery. Titled "Multidimensional Characterization of Tumor–Immune Architecture Reveals Biologically Distinct Subtypes of Classic Hodgkin Lymphoma," the paper unveils four distinct biological subtypes, challenging the one-size-fits-all approach to therapy and paving the way for precision medicine.

This discovery stems from an integrative analysis of tumor samples, highlighting how genetic mutations and interactions within the tumor microenvironment (TME)—the ecosystem of surrounding immune cells—drive different disease behaviors. For Canadian patients, where approximately 1,150 new cases of Hodgkin lymphoma are diagnosed annually, this could mean more targeted treatments and improved outcomes in a disease with an already high five-year survival rate of around 89 percent.

What Is Hodgkin Lymphoma? A Primer for Canadians

Hodgkin lymphoma originates in the lymphatic system, part of the body's immune network that fights infection. Named after Thomas Hodgkin, who described it in 1832, it primarily affects young adults aged 15 to 40 and older adults over 55. In Canada, the Canadian Cancer Society estimates 650 men and 530 women will be diagnosed in 2025, with 120 deaths—75 among men and 45 among women. While incidence has remained stable, advances in chemotherapy and immunotherapy have boosted survival rates significantly over the past decades.

Symptoms often include painless swelling of lymph nodes in the neck, armpits, or groin, fever, night sweats, unexplained weight loss, and fatigue. Early detection through biopsy and staging via PET-CT scans is crucial. Standard treatment involves ABVD chemotherapy (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) combined with radiation for early stages, achieving cure rates over 90 percent in favorable cases. Yet, relapsed or refractory cases pose challenges, underscoring the need for subtype-specific strategies.

The Innovative Methods Behind the UBC Discovery

The UBC-led team, drawing from the Lymphoid Cancer Research group at BC Cancer, employed a multimodal approach to dissect cHL tumors. They sequenced malignant HRS cells, applied spatial transcriptomics to map gene expression in tissue context, and used imaging mass cytometry to visualize protein markers across hundreds of immune cell types simultaneously. This systems-level profiling of over 100 patient samples revealed patterns invisible to traditional histology.

Step-by-step, the process began with laser-capture microdissection to isolate HRS cells, followed by whole-exome and RNA sequencing. Spatial technologies like NanoString GeoMx and Ionpath Hyperion provided micron-level resolution of the TME. Machine learning clustered data into subtypes, validated against clinical outcomes like progression-free survival.

This rigorous methodology not only confirmed known cHL hallmarks—like NF-κB pathway activation—but uncovered novel subtype-defining features.

Unpacking the Four New Subtypes: CST, CN913, STB, and CN2P

The HLGen classification identifies four subtypes, each with unique genetic drivers and immune profiles:

• CST (CSF2RB-mutated Subtype): Defined by mutations in the CSF2RB gene, leading to dysregulated signaling and high TARC (thymus and activation-regulated chemokine) secretion. This creates an immunosuppressive niche, recruiting regulatory T cells that shield cancer cells.
• CN913: Characterized by copy number alterations in genes like CN9 and 13, associated with aggressive proliferation and distinct stromal interactions.
• STB (Stromal Tumor-rich B-cell): Features robust stromal support and B-cell infiltration, potentially responsive to stroma-targeting agents.
• CN2P: Marked by specific copy number gains/losses, showing varied immune exhaustion patterns.

These subtypes correlate with clinical traits: CST shows poorer response to certain immunotherapies, while others may benefit from PD-1 inhibitors like nivolumab.

Implications for Treatment: Toward Precision Oncology

Traditionally, cHL staging relies on Ann Arbor criteria, but HLGen adds molecular precision. For instance, modeling CSF2RB mutations in preclinical assays revealed targetable vulnerabilities, like JAK-STAT inhibitors. This could stratify patients for trials, sparing low-risk subtypes from overtreatment and directing high-risk ones to novel agents.

In Canada, where BC Cancer leads national trials via the Canadian Cancer Trials Group, integrating HLGen could optimize resource use. Read the full study to explore therapeutic opportunities.

Experts anticipate subtype-guided trials accelerating approvals for drugs like brentuximab vedotin conjugates.

Spotlight on UBC's Research Leaders: Christian Steidl and Team

Principal investigator Dr. Christian Steidl, Professor of Pathology and Laboratory Medicine at UBC and Executive Director of Research at BC Cancer, has pioneered genomic profiling in lymphomas. His lab's prior discoveries include MHC-deficient subtypes. Lead author Dr. Tomohiro Aoki, now at Princess Margaret Cancer Centre, bridged clinical and lab insights.

The multidisciplinary team included experts in bioinformatics (Andrew Roth, UBC) and immunology (Brad Nelson). Funded by the Terry Fox Research Institute and BC Cancer Foundation, this exemplifies UBC's role in translational research. Aspiring researchers can find opportunities in higher ed research jobs.

Hodgkin Lymphoma in Canada: Current Landscape and Challenges

Canada's universal healthcare ensures equitable access, yet regional disparities persist—higher incidence in younger populations in provinces like British Columbia and Ontario. Survival exceeds 90 percent for early-stage but drops to 65 percent for advanced. Late effects like secondary cancers from therapy affect 20-30 percent of survivors.

Recent developments include frontline immunotherapy integration, as per Canadian Hematology Society guidelines. BC Cancer's Lymphoid Cancer Research drives national progress. For context, explore Canadian higher education opportunities.

Future Outlook: Clinical Trials and Global Impact

HLGen was awarded the Karl Mussoff Prize at the 2024 International Symposium on Hodgkin Lymphoma. Upcoming trials will test subtype-specific therapies, potentially incorporating bispecific antibodies. Globally, this refines WHO classifications, benefiting 80,000 annual cases.

In Canada, collaborations with Genome Canada enable scalable diagnostics. Long-term, AI-enhanced spatial profiling could predict relapses pre-symptomatically.

Career Pathways in Cancer Research at Institutions Like UBC

This study highlights UBC's ecosystem for lymphoma research, from postdocs to faculty. Roles span pathology, bioinformatics, and clinical trials. With demand surging, check clinical research jobs or research assistant positions. Craft a winning academic CV to join leaders like Steidl.

Rate professors via Rate My Professor for insights into UBC's Pathology department.

Photo by Jana Ohajdova on Unsplash

Why This Matters: Empowering Patients and Researchers

For patients, subtypes mean hope for tailored therapies reducing toxicity. Researchers gain a framework for drug development. As UBC advances precision oncology, explore university jobs, higher ed jobs, and career advice. Share your story in comments and connect via postdoc opportunities.